Studies from Sichuan University Add New Findings in the Area of Lung Cancer (Bulk and single-cell RNA sequencing reveal the contribution of laminin g2 -CD44 to the immune resistance in lymphocyte-infiltrated squamous lung cancer subtype).

A study conducted by researchers at Sichuan University in Chengdu, China, has found that the high heterogeneity of lung squamous cell carcinomas (LUSC) and the complex tumor microenvironment contribute to non-response to immunotherapy in many patients. The researchers analyzed RNA sequencing data from 513 LUSC samples and identified six subtypes based on the data. They found that one subtype, CS3, exhibited resistance to immune checkpoint blockade therapy and had high levels of lymphocyte infiltration. The study also revealed a positive relationship between the expression of LAMC2-CD44 and immune resistance. The researchers suggest that targeting this molecule pair in combination with immunotherapy could potentially improve treatment efficacy. [Extracted from the article]

Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)